Clinical Trial Goal
To find out if mosunetuzumab is safe and works well to treat follicular lymphoma that has not yet been treated
You may be able to join this trial if you:
- Are 18 years old or older
- Have newly diagnosed follicular lymphoma that needs treatment
- Have not received any treatment for the lymphoma
- Do not have lymphoma in your brain or spinal cord
- Have not had a blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Mosunetuzumab is a T-cell engaging bispecific antibody that target CD20 and CD3 on certain cells.
You’ll get:
You’ll get:
- Mosunetuzumab – Given as a shot under your skin 1 time each week for 4 weeks, then 1 time every 3 weeks
You may continue treatment for about 6-12 months depending on how well it's working. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved mosunetuzumab to treat follicular lymphoma that has that has come back (relapsed) or has not gotten better with treatment (refractory).
Contacts
Lorenzo Falchi, MD, 646-608-3705, FalchiL@mskcc.org
Gilles Salles, MD, PhD, 646-608-4153, SallesG@mskcc.org
Locations
Sponsors
lead: Memorial Sloan Kettering Cancer Center
